Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Maximum Tolerated Dose, Dose Limiting
Toxicities and optimal dosing schedule of 4SC-202 investigating its safety, tolerability and
pharmacokinetics.